Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

68Ga-NODAGA-exendin-4 PET/CT for Diagnostic Imaging in AHH (GLP-1-AHH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03189953
Recruitment Status : Unknown
Verified May 2017 by Radboud University.
Recruitment status was:  Enrolling by invitation
First Posted : June 16, 2017
Last Update Posted : May 3, 2018
Sponsor:
Collaborators:
University Medical Center Groningen
Charite University, Berlin, Germany
University Hospital, Basel, Switzerland
University Hospital Inselspital, Berne
University College, London
Helsinki University
University of Turku
Information provided by (Responsible Party):
Radboud University

Brief Summary:
In order to improve the sensitivity and specificity of pre-operative imaging localization of foci in adult endogenous hyperinsulinemic hypoglycaemia (AHH) we aim to evaluate a novel promising imaging compound targeting the glucagon-like peptide-1 receptor (GLP-1R), 68Ga-NODAGA-exendin 4. With the currently used imaging techniques, only about 70-80% of insulin producing pancreatic neuroendocrine tumors (IPPNET) can be successfully visualized. Therefore, we propose to compare GLP-1R PET imaging to the standard imaging techniques in patients scheduled for surgical removal of the tumour. These highly relevant data will allow us to interpret the benefits of GLP-1R-imaging over other imaging techniques for the diagnosis of IPPNET in AHH patients. Since pre-operative localization of foci in AHH remains challenging and frequently still leading to futile surgery or unnecessary partial pancreatectomy, a more sensitive and specific imaging technique would be of great value.

Condition or disease Intervention/treatment Phase
Insulinoma Radiation: 68Ga-NODAGA-exendin 4 PET/CT Phase 1 Phase 2

Detailed Description:

Adult endogenous hyperinsulinaemic hypoglycaemia The most common form of functional neuroendocrine tumours of the pancreas are insulin producing pancreatic neuroendocrine tumors (IPPNET). These tumors are rare and have an incidence of 1-4 newly diagnosed cases per 1 million per year and are malignant in about 10% of the cases. Another cause of AHH is nesidioblastosis, or adult beta cell hyperplasia. It is difficult to exactly determine the incidence of the disease, but it appears that in approximately 5% of the cases of AHH nesiodioblastosis may be the underlying pathology, while IPPNET are responsible for the majority of the cases. The pathophysiological cause of nesidioblastosis is not well understood, but the rising incidence of the AHH as a consequence of gastric bypass surgery for morbid obesity (although often reversible in these patients) may suggest an association with metabolic and hormonal changes.

For IPPNET, surgical removal of the tumour is the therapy of choice and is considered curative in case of a benign tumour. Optimal preoperative localization of the lesion is warranted in order to reduce morbidity by helping to optimize the surgical procedure. Successful preoperative localization of IPPNET is a challenging problem since approximately 30% of IPPNET cannot be visualized using the conventional imaging techniques CT and/or MRI and endoscopic ultrasound. Selective arterial stimulation with calcium with simultaneous venous sampling (ASVS) has been described to have a sensitivity and specificity of almost 90% in identifying IPPNET. This is, however, an invasive technique which is accompanied by an risk for complications. Functional imaging with somatostatin (sst) receptor scintigraphy (SRS) and SPECT/CT are able to detect less than 50% of benign IPPNET because of low or absent expression of sst receptor subtypes 2 and 5, which bind octreotide with high affinity. PET with 68Ga-labeled sst analogs has a higher sensitivity for smaller lesions than SRS. Also 11C-5-HTP and 18F-DOPA, which are used as PET tracers for the detection of IPPNET in some centers may be more sensitive than SRS and CT with 11C-5-HTP showing the most accurate visualization. However, when compared to intra-operative findings, 2 out of 6 IPPNET could still not be detected preoperatively. Palpation and intra-operative ultrasound will allow identifying the lesion in approximately 70-80% of cases. However, it remains a challenge to find small or multiple tumours in the pancreas and partial pancreatectomy is frequently required, especially if the lesion is located close to the pancreatic duct. Precise preoperative localization of the IPPNET is therefore critical to minimize surgical intervention. If no IPPNET can be identified pre- or perioperatively, the diagnosis of nesidioblastosis may be established by resection and histopathologic evaluation of the pancreatic tail. If nesidioblastosis is present, partial pancreatectomy is required; the challenge is to remove enough tissue in order to avoid hypoglycaemia while keeping enough functional endocrine pancreatic tissue so that the patient does not become diabetic. Currently, with the risk of reoperation being considered lower than the consequences and complications of diabetes, surgeons usually choose a fairly conservative approach.

Imaging of diseased beta cells Visualization of the beta cells by a highly specific radiotracer with which high target-to background ratios can be obtained would benefit preoperative visualization of IPPNET in patients with AHH. Reliable visualization of diseased beta cells would then benefit the optimization of treatment of patients with AHH. An innovative method for imaging of beta cells could allow to optimally guide surgical interventions In addition, this novel approach could lead to a minimization of side-effects from the treatment.

Targeting of the GLP-1 receptor In this study we will compare the sensitivity and specificity of pre-operative imaging of IPPNET by GLP-1R scanning to the current standard imaging techniques.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Comparison of 68Ga-NODAGA-exendin PET/CT with standard diagnostic methods
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: 68Ga-NODAGA-exendin-4 PET/CT in Patients With AHH - a Prospective Comparative Evaluation of Preoperative Imaging
Study Start Date : April 2015
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine

Drug Information available for: Exenatide

Arm Intervention/treatment
Experimental: 68Ga-NODAGA-exendin PET/CT
68Ga-NODAGA-exendin PET/CT
Radiation: 68Ga-NODAGA-exendin 4 PET/CT
68Ga-NODAGA-exendin 4 PET/CT




Primary Outcome Measures :
  1. Tumor visualization by 68Ga-NODAGA-exendin-4 PET/CT and standard imaging [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Calculation of the organ- and effective dose of 68Ga-NODAGA-exendin 4 [ Time Frame: 1 year ]
  2. Retrospective surgery planning, type of surgery based on image analysis [ Time Frame: 1 year ]
  3. Calculation and comparison of the interobserver variability of 68Ga-NODAGA-exendin 4 PET/CT and EUS combined with triple phase CT or MRI [ Time Frame: up to 24 months ]
  4. GLP-1 receptor expression by histology compared to tracer uptake [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biochemically proven endogenous hyperinsulinemic hypoglycemia
  • Signed informed consent
  • Standard imaging not older than 8 weeks.

Exclusion Criteria:

  • Breast feeding
  • Pregnancy or the wish to become pregnant within 6 months
  • Calculated creatinine clearance below 40ml/min
  • Evidence of other malignancy than insulin producing tumors in conventional imaging (suspicious liver, bone and lung lesions)
  • Age < 18 years
  • No signed informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03189953


Sponsors and Collaborators
Radboud University
University Medical Center Groningen
Charite University, Berlin, Germany
University Hospital, Basel, Switzerland
University Hospital Inselspital, Berne
University College, London
Helsinki University
University of Turku
Investigators
Layout table for investigator information
Principal Investigator: Martin Gotthardt, Prof. Dr. Radboud University

Layout table for additonal information
Responsible Party: Radboud University
ClinicalTrials.gov Identifier: NCT03189953     History of Changes
Other Study ID Numbers: NL50643.091.14
2014-003167-38 ( EudraCT Number )
602812 ( Other Grant/Funding Number: European Commission )
First Posted: June 16, 2017    Key Record Dates
Last Update Posted: May 3, 2018
Last Verified: May 2017

Additional relevant MeSH terms:
Layout table for MeSH terms
Insulinoma
Adenoma, Islet Cell
Adenoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Exenatide
Hypoglycemic Agents
Physiological Effects of Drugs
Anti-Obesity Agents
Incretins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists